Prostate Cancer Foundation of Australia shared on LinkedIn:
”If you’re a health expert, you understand the social determinants of health.
But it’s also time we talked about the regulatory determinants of life and death in Australia.
Stuart Auckland had run out of options for metastatic prostate cancer when he began Lutetium-177 PSMA therapy on a clinical trial in late 2024. By his fifth cycle of treatment, most of his smaller tumours had disappeared from his scans. He has since seen his daughter get married and has returned to enjoying a quality of life he never thought he’d experience again.
Natasha Robinson’s story in The Australian on the weekend explains why most men in his position won’t get the same chance. The barrier is not the science. It is how we have chosen to classify, assess and fund it:
Radiopharmaceuticals are classed as services, not medicines, so subsidy applications go to MSAC and the MBS. That pathway was never designed to negotiate the price of a therapeutic product.
Medicare rebates often fall well short of the actual cost, leaving men to find around $50,000 upfront.
In-house compounding in our major cancer hospitals has stopped following a patent dispute, so public access is now largely confined to clinical trials.
The result is a public-private divide in a field where Australia leads the world in Families are crowdfunding, traveling overseas, or going without a therapy estimated to be suitable for about a third of men with prostate cancer. For these men, survival is being determined by their bank balance and by a classification decision, not by clinical need
Prostate Cancer Foundation of Australia is joining clinicians, industry and patient groups in calling for a dedicated Radiopharmaceutical Benefits Scheme: an assessment and funding pathway built for these therapies.
If you work in health technology assessment, nuclear medicine, hospital pharmacy or cancer services planning, please raise your voice: we need fit-for-purpose pathways to save lives.”
You can also read:
PR21 Trial Compares Patient-Reported Outcomes With Lu-177 PSMA-617 and Docetaxel in mCRPC
